Navigation Links
Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008
Date:3/12/2009

BETHESDA, Md., March 12 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it is regaining from its partner MedImmune the rights in North America to its most advanced BiTE antibody candidate, blinatumomab, also known as MT103. In Europe, Micromet is conducting a phase 2 clinical trial with blinatumomab for the treatment of patients with acute lymphoblastic leukemia and a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. In addition, the two companies plan to initiate a research program for the development of a new BiTE antibody for the treatment of hematological cancers. Micromet also announced its financial results for the fourth quarter and full year ended December 31, 2008.

"We had a successful 2008 and are excited about the prospects for 2009. Our lead BiTE antibody program blinatumomab reported encouraging clinical data from phase 1 and phase 2 clinical trials last year, which form the basis for advancing the program towards its first pivotal clinical trial. We are pleased to regain North American rights to blinatumomab from our partner and are looking forward to taking control of the worldwide development of the program," stated Christian Itin, President and Chief Executive Officer of Micromet. "With our successful financing and partnering activities last year and early this year, we are well positioned to move our programs to the next value step."

Recent Developments relating to Blinatumomab and Micromet's Collaboration with MedImmune:

In March 2009, MedImmune elected to return its license rights to blinatumomab to Micromet. Micromet will assume responsibility for the worldwide clinical development
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Micromet, Inc. Reports Third Quarter 2008 Financial Results
2. Micromet, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results
3. Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule
4. Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer
5. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
6. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
7. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
8. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
9. Verenium Regains Compliance With Nasdaq Continued Listing Requirement
10. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
11. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... today (August 22nd), in the scientific journal ... Programme establish the effect of serotonin on sensitivity ... and optical techniques., "Serotonin is a small molecule ... of brain functions, from the control of sleep ... behaviours, This neurotransmitter is also popularly thought to ...
(Date:8/22/2014)... Ophthalmic drug delivery technologies or ... endeavors as the anatomy, physiology and biochemistry of ... foreign substances. Ocular drug delivery technologies provide several ... minimal use of needles; also it enables high ... specific targeting within the ocular globe. On the ...
(Date:8/22/2014)... Research and Markets has announced the addition ... Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - ... The global molecular biology enzymes market was ... to grow at a CAGR of 13.74% to reach ... reagents find applications in a large number of fields ...
(Date:8/22/2014)... 22, 2014 The identification of ... can be accelerated by exome sequencing. Built on ... the custom SeqCap EZ Developer system has been ... Watson will additionally present how he achieved coverage ... human and mouse exome kits. With over 236,000 ...
Breaking Biology Technology:From happiness to pain: Understanding serotonin's function 2Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4Global Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - Forecast to 2018 2Global Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - Forecast to 2018 3Efficient Identification of Protein-Coding Variants in a Model Organism Through Exome Sequencing, New Webinar Hosted by Xtalks 2
... provides the Company and investor an option to sell or ... purchase additional $67.5 million in securities, SEATTLE, April ... CTIC ; MTA) today announced that it has,entered into agreements ... Series E Convertible Preferred Stock (the "Preferred,Stock"), 13.5% Convertible Senior ...
... 29 Onyx,Pharmaceuticals, Inc. (Nasdaq: ONXX ) today ... discuss first quarter 2008 financial,results and provide a general ... Eastern Time (2:00 p.m. Pacific Time). Financial results for ... earlier that day., Interested parties may access a ...
... SOUTH SAN FRANCISCO, Calif., April 29 ,Anesiva, Inc. ... exclusive Zingo(TM),marketing and distribution agreement, with Green Vision ... powder intradermal injection system is approved in the ... IV insertions or blood,draws in children three to ...
Cached Biology Technology:Cell Therapeutics, Inc. Sells $64.5 million Units Consisting of Preferred Stock, New 2014 Convertible Senior Notes and Warrants to a Single Institutional Investor 2Cell Therapeutics, Inc. Sells $64.5 million Units Consisting of Preferred Stock, New 2014 Convertible Senior Notes and Warrants to a Single Institutional Investor 3Anesiva Announces New Zingo Marketing and Distribution Agreement 2Anesiva Announces New Zingo Marketing and Distribution Agreement 3
(Date:8/21/2014)... Aug. 21, 2014 Nxt-ID, Inc. (OTCQB: NXTD), ... commerce market, announced today that its shares of common ... be issued in its proposed underwritten public offering of ... on The Nasdaq Capital Market, subject to closing of ... and warrants, and will trade under the symbol "NXTD" ...
(Date:8/21/2014)... dandruff, eczema and other itchy, flaky maladies in humans ... Hawaiian coral reefs and the extreme environments of arctic ... the scientific journal PLOS Pathogens considers the ... genus Malassezia in light of new insights ... world. , University of Hawai,i at Mānoa scientist Anthony ...
(Date:8/21/2014)... researchers from Beth Israel Deaconess Medical Center (BIDMC ) ... Most Influential Scientific Minds 2014," a comprehensive list ... web resource for science metrics and research performance analysis. ... most influential "are performing and publishing work that their ... science," according to a Thomson Reuters statement. Researchers were ...
Breaking Biology News(10 mins):Nxt-ID Approved for NASDAQ Capital Market Listing 2Nxt-ID Approved for NASDAQ Capital Market Listing 3From dandruff to deep sea vents, an ecologically hyper-diverse fungus 2BIDMC researchers named among 'the most influential scientific minds' 2BIDMC researchers named among 'the most influential scientific minds' 3
... at the Virginia Bioinformatics Institute and Duke University ... appears to play an important role in the ... brassicicola, a destructive fungal pathogen that causes black ... results in considerable leaf loss in many economically ...
... practice of killing wild badgers to prevent tuberculosis in ... led by Rosie Woodroffe, an ecologist at the University ... Group on Cattle TB. , In Britain, farming interests ... the merits of culling badgers to fight cattle tuberculosis, ...
... life--large, small, and microscopic. Bacteriophage (phage) viruses are minute, ... their communities through predation and parasitism. Despite their small ... of them in a bucket full of seawater as ... they can have a huge impact ecologically. , ...
Cached Biology News:Tearing down the fungal cell wall 2Tearing down the fungal cell wall 3British cattle give TB to badgers, finds UC Davis expert 2Hundreds of thousands of viral species present in the world's oceans 2
Rabbit Polyclonal antibody to Perilipin Applications: This antibody is useful for Western blot anlaysis where a band at ~60 kDa is seen....
... A thermostable, thermoactive designer enzyme ... single-tube-reaction. AccuRT RNA PCR enzyme allows ... be performed at elevated temperatures (65C), ... from the template and results in ...
Request Info...
EML1 (K-16)...
Biology Products: